<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>35 patients with oral <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> (OAC) related intracranial or intraspinal haemorrhage were studied to determine treatment received, outcome and rate of recurrent <z:mp ids='MP_0001914'>bleeding</z:mp> and <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> after restarting OAC </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients underwent active <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> reversal and in 14 patients with prosthetic heart valves (<z:chebi fb="0" ids="53390">PHV</z:chebi>) the INR remained below 2.0 for 0-19d (median 7) with no <z:hpo ids='HP_0001907'>thromboembolic events</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>10 patients received <z:chebi fb="5" ids="28304">heparin</z:chebi>, although a therapeutic level was rarely achieved </plain></SENT>
<SENT sid="3" pm="."><plain>13 patients with <z:chebi fb="0" ids="53390">PHV</z:chebi> were restarted on OAC and followed for a median 23.5 months </plain></SENT>
<SENT sid="4" pm="."><plain>One patient had recurrent <z:mp ids='MP_0001915'>intracranial bleeding</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>3/13 patients had cerebral embolic events despite anticoagulation </plain></SENT>
<SENT sid="6" pm="."><plain>We conclude that in <z:chebi fb="0" ids="53390">PHV</z:chebi> patients temporary cessation of OAC is safe and the risk of recurrent <z:mp ids='MP_0001914'>bleeding</z:mp> after restarting OAC is low </plain></SENT>
</text></document>